The United States Food and Drug Administration has finally agreed to introduce the first treatment for tardive dyskinesia on the market. The producer of the valbenazine capsules called INGREZZA is Neurocrine Biosciences Inc. The company has been actively working in the fields of endocrine and neurological disorders since 1992.
Tardive Dyskinesia Is a Side Effect of Antipsychotic Drugs
Tardive dyskinesia has generated many incurable cases throughout the years. This condition is a complicated form of dyskinesia which is a neurological disorder that causes involuntary and repetitional body movements. This illness can occur only as a side effect of antipsychotic drugs that have been administered for at least three months. In children, the medication for gastrointestinal disorders can produce the same neurological defect.
Before INGREZZA, all the recommended medication had dangerous side effects. Moreover, patients had to use them with careful attention and in small dosages so as not to develop tolerance. On the other hand, the valbenazine capsules introduced a new, selective vesicular monoamine transporter 2 also called as a VMAT2 inhibitor. It is also the first drug that the FDA approved as intended especially for tardive dyskinesia developed in adults.
The company announced that it is ready to distribute INGREZZA as soon as possible. As a consequence, the new pills will appear on shelves as of next week. However, the product will be available only for a selected list of pharmacies. On May 1, 2017, healthcare professionals will receive green light for promotion.
There Are Around 500,000 Americans Who Developed this Condition
On Tuesday, Neurocrine closed the trading market at $41.48 which enjoyed an increase of $1.17 in the wake of the news. The after-hours trade added another $8.02 or 19.33% to the total value of the stock. The company has also announced the price range for its first ever commercial product. It is going to start from a basic price of $20,000 and can go up to $60,000 a year. However, the price tag will vary from person to person, depending on the needed dosage.
The CEO of Neurocrine Biosciences, Kevin Gorman, stated that there are approximately 500,000 Americans who suffer from this condition. He claimed that the product would have a minimum number of clients of 50,000 persons.
The FDA followed its acceptance with a list of warnings. The INGREZZA consumption can lead to several side effects, including drowsiness and heart rhythm problems. Patients with congenital long QT syndrome as well as those with irregular heartbeats should avoid the use of the new drug by all means.
Image source: 1